drugset / Trial / NCT02781311
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
Timeline
- Start
- 2016-07-14
- Primary completion
- 2018-03-15
- Completion
- 2018-05-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Finasteride | Small molecule | 1 mg | Oral |
| Subject | Setipiprant | Small molecule | 1000 mg | Oral |